CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Emergent BioSolutions Inc. - EBS CFD

2.84
4.03%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-1.05)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.16)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Emergent BioSolutions Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 2.73
Open* 2.76
1-Year Change* -79.69%
Day's Range* 2.74 - 3.02
52 wk Range 1.81-16.66
Average Volume (10 days) 1.35M
Average Volume (3 months) 28.43M
Market Cap 95.47M
P/E Ratio -100.00K
Shares Outstanding 51.88M
Revenue 1.10B
EPS -15.32
Dividend (Yield %) N/A
Beta 1.00
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 26, 2024 2.84 0.17 6.37% 2.67 3.05 2.67
Feb 23, 2024 2.72 0.04 1.49% 2.68 3.21 2.66
Feb 22, 2024 2.79 0.15 5.68% 2.64 2.96 2.44
Feb 21, 2024 2.67 1.05 64.81% 1.62 3.23 1.62
Feb 20, 2024 1.50 -0.04 -2.60% 1.54 1.59 1.45
Feb 16, 2024 1.54 -0.05 -3.14% 1.59 1.64 1.53
Feb 15, 2024 1.68 0.01 0.60% 1.67 1.72 1.62
Feb 14, 2024 1.66 0.10 6.41% 1.56 1.69 1.51
Feb 13, 2024 1.57 -0.05 -3.09% 1.62 1.67 1.56
Feb 12, 2024 1.78 0.18 11.25% 1.60 1.81 1.57
Feb 9, 2024 1.56 -0.07 -4.29% 1.63 1.65 1.50
Feb 8, 2024 1.65 0.15 10.00% 1.50 1.65 1.45
Feb 7, 2024 1.47 -0.08 -5.16% 1.55 1.57 1.45
Feb 6, 2024 1.54 0.04 2.67% 1.50 1.56 1.40
Feb 5, 2024 1.50 -0.07 -4.46% 1.57 1.57 1.48
Feb 2, 2024 1.60 0.00 0.00% 1.60 1.62 1.54
Feb 1, 2024 1.62 -0.04 -2.41% 1.66 1.73 1.59
Jan 31, 2024 1.65 -0.03 -1.79% 1.68 1.78 1.65
Jan 30, 2024 1.71 -0.07 -3.93% 1.78 1.82 1.71
Jan 29, 2024 1.81 0.00 0.00% 1.81 1.82 1.74

Emergent BioSolutions Inc. Events

Time (UTC) Country Event
Tuesday, February 27, 2024

Time (UTC)

21:00

Country

US

Event

Q4 2023 Emergent BioSolutions Inc Earnings Release
Q4 2023 Emergent BioSolutions Inc Earnings Release

Forecast

-

Previous

-
Friday, May 24, 2024

Time (UTC)

13:00

Country

US

Event

Emergent BioSolutions Inc Annual Shareholders Meeting
Emergent BioSolutions Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1120.9 1792.7 1555.4 1106 782.4
Revenue 1120.9 1792.7 1555.4 1106 782.4
Cost of Revenue, Total 693.7 716 506.7 433.5 322.3
Gross Profit 427.2 1076.7 1048.7 672.5 460.1
Total Operating Expense 1293.6 1440.1 1121.6 991.9 692.6
Selling/General/Admin. Expenses, Total 340.3 348.4 303.3 273.5 202.5
Research & Development 193 234 205.5 226.2 142.8
Operating Income -172.7 352.6 433.8 114.1 89.8
Interest Income (Expense), Net Non-Operating -37.3 -34.5 -31.3 -38.4 -9.9
Other, Net -11.7 -3.7 4.7 1.7 1.6
Net Income Before Taxes -221.7 314.4 407.2 77.4 81.5
Net Income After Taxes -223.8 230.9 305.1 54.5 58.4
Net Income Before Extra. Items -223.8 230.9 305.1 54.5 58.4
Total Extraordinary Items 0 4.3
Net Income -223.8 230.9 305.1 54.5 62.7
Income Available to Common Excl. Extra. Items -223.8 230.9 305.1 54.5 58.4
Income Available to Common Incl. Extra. Items -223.8 230.9 305.1 54.5 62.7
Diluted Net Income -223.8 230.9 305.1 54.5 62.7
Diluted Weighted Average Shares 50.1 54.1 53.8 52.4 51.4
Diluted EPS Excluding Extraordinary Items -4.46707 4.26802 5.671 1.04008 1.13619
Diluted Normalized EPS -4.38014 5.39747 6.31582 1.04008 1.13619
Depreciation / Amortization 59.9 58.5 59.8 58.7 25
Unusual Expense (Income) 6.7 83.2 46.3
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 337.9 165.1 330.7 240 242.7
Revenue 337.9 165.1 330.7 240 242.7
Cost of Revenue, Total 190.6 155.1 219.4 148.6 169.8
Gross Profit 147.3 10 111.3 91.4 72.9
Total Operating Expense 555.9 313.2 395.8 282 314.7
Selling/General/Admin. Expenses, Total 91.4 100.5 94.2 80.2 81.1
Research & Development 26 40.6 57.6 39.2 49.8
Depreciation / Amortization 16.1 17 17.9 14 14
Operating Income -218 -148.1 -65.1 -42 -72
Interest Income (Expense), Net Non-Operating -28.6 -17.9 -12.8 -8.5 -7.8
Other, Net -3.6 4.9 6.7 -13.4 -3
Net Income Before Taxes -250.2 -161.1 -71.2 -63.9 -82.8
Net Income After Taxes -261.3 -183 -88 -75.7 -56.4
Net Income Before Extra. Items -261.3 -183 -88 -75.7 -56.4
Net Income -261.3 -183 -88 -75.7 -56.4
Income Available to Common Excl. Extra. Items -261.3 -183 -88 -75.7 -56.4
Income Available to Common Incl. Extra. Items -261.3 -183 -88 -75.7 -56.4
Diluted Net Income -261.3 -183 -88 -75.7 -56.4
Diluted Weighted Average Shares 50.7 50.2 49.8 49.9 50
Diluted EPS Excluding Extraordinary Items -5.15385 -3.64542 -1.76707 -1.51703 -1.128
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.18205 -3.64542 -1.67962 -1.51703 -1.128
Unusual Expense (Income) 231.8 6.7
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1210.7 1272.1 1195.9 686.2 620.8
Cash and Short Term Investments 642.6 576.1 621.3 167.8 112.2
Cash & Equivalents 642.6 576.1 621.3 167.8 112.2
Total Receivables, Net 158.4 274.7 272 275.3 271.1
Accounts Receivable - Trade, Net 158.4 274.7 272 270.7 262.5
Total Inventory 351.8 350.8 307 222.5 205.8
Prepaid Expenses 57.9 70.3 -4.6 20.4 31.5
Other Current Assets, Total 0 0.2 0.2 0.2 0.2
Total Assets 3166.6 2959 2883.2 2327.3 2229.4
Property/Plant/Equipment, Total - Net 837 828.4 675.1 567 510.2
Property/Plant/Equipment, Total - Gross 1220.8 1147.5 934.2 777.4 681.7
Accumulated Depreciation, Total -383.8 -319.1 -259.1 -210.4 -171.5
Goodwill, Net 218.2 224.9 266.7 266.6 259.7
Intangibles, Net 728.8 604.6 663.1 741.9 811.6
Other Long Term Assets, Total 171.9 29 82.4 65.6 27.1
Total Current Liabilities 1229.9 373.8 384.5 216.3 200.4
Accounts Payable 103.5 128.9 136.1 94.8 80.7
Accrued Expenses 129 146.2 136.9 105.5 88.9
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 40.1 67.1 77.7 3.1 20.7
Total Liabilities 1783.6 1340 1436.2 1238.8 1218.5
Total Long Term Debt 448.5 809.4 841 798.4 784.5
Long Term Debt 448.5 809.4 841 798.4 784.5
Other Liabilities, Total 33.4 61.9 157.5 160.2 166.1
Total Equity 1383 1619 1447 1088.5 1010.9
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.1 0.1 0.1 0.1 0.1
Additional Paid-In Capital 873.5 829.4 784.9 716.1 688.6
Retained Earnings (Accumulated Deficit) 734 957.8 726.9 421.8 367.3
Treasury Stock - Common -227.7 -152.2 -39.6 -39.6 -39.6
Other Equity, Total 3.1 -16.1 -25.3 -9.9 -5.5
Total Liabilities & Shareholders’ Equity 3166.6 2959 2883.2 2327.3 2229.4
Total Common Shares Outstanding 50.1 51.3 53.1 51.7 51.2
Total Preferred Shares Outstanding 0 0
Current Port. of LT Debt/Capital Leases 957.3 31.6 33.8 12.9 10.1
Deferred Income Tax 71.8 94.9 53.2 63.9 67.5
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total Current Assets 777.7 1221.3 1210.7 1118.5 1084.2
Cash and Short Term Investments 88.6 430.2 642.6 240.9 358.1
Cash & Equivalents 88.6 430.2 642.6 240.9 358.1
Total Receivables, Net 290.1 155.9 158.4 191.3 175
Accounts Receivable - Trade, Net 290.1 155.9 158.4 191.3 175
Total Inventory 354.3 367.9 351.8 546.3 425.5
Prepaid Expenses 44.7 41.7 57.9 139.9 125.4
Other Current Assets, Total 225.6 0 0.1 0.2
Total Assets 2178.8 2949.8 3166.6 2908.5 2735.4
Property/Plant/Equipment, Total - Net 411.2 732.3 837 827.2 823.9
Property/Plant/Equipment, Total - Gross 802.6 1107.5 1220.8 1193.4 1181.6
Accumulated Depreciation, Total -391.4 -375.2 -383.8 -366.2 -357.7
Goodwill, Net 218.2 218.2 218.2 224.9 224.9
Intangibles, Net 592.8 608.9 728.8 722.7 576.6
Other Long Term Assets, Total 178.9 169.1 171.9 15.2 25.8
Total Current Liabilities 693.2 1215.7 1229.9 268.4 276.7
Accounts Payable 108.3 124.2 103.5 103.8 106.2
Accrued Expenses 104.4 81.5 129 124.1 120.6
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 455.2 950.7 957.3 21.2 31.6
Other Current Liabilities, Total 25.3 59.3 40.1 19.3 18.3
Total Liabilities 1222.5 1747.2 1783.6 1459.2 1222.2
Total Long Term Debt 448 447.7 448.5 1032.1 793.6
Long Term Debt 448 447.7 448.5 1032.1 793.6
Deferred Income Tax 57.9 59.7 71.8 113.8 93.4
Other Liabilities, Total 23.4 24.1 33.4 44.9 58.5
Total Equity 956.3 1202.6 1383 1449.3 1513.2
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.1 0.1 0.1 0.1 0.1
Additional Paid-In Capital 895.8 878.2 873.5 860.1 849.2
Retained Earnings (Accumulated Deficit) 289.7 551 734 822 897.7
Treasury Stock - Common -227.7 -227.7 -227.7 -227.7 -227.7
Other Equity, Total -1.6 1 3.1 -5.2 -6.1
Total Liabilities & Shareholders’ Equity 2178.8 2949.8 3166.6 2908.5 2735.4
Total Common Shares Outstanding 51.8 50.4 50.1 49.9 49.9
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -223.8 230.9 305.1 54.5 62.7
Cash From Operating Activities -34.1 321.1 536 188 41.8
Cash From Operating Activities 143.3 123.8 114.5 110.7 62.2
Deferred Taxes -19 46.9 -2.4 -1.1 8.6
Non-Cash Items 64.9 75.9 110 66.3 27.4
Cash Taxes Paid 6.2 71.6 109.3 30.8 14
Cash Interest Paid 33 30.4 21 34.5 10.2
Changes in Working Capital 0.5 -156.4 8.8 -42.4 -119.1
Cash From Investing Activities -381.3 -225 -151 -96.9 -897.2
Capital Expenditures -359.5 -225 -151 -96.9 -72.1
Other Investing Cash Flow Items, Total -21.8 0 -825.1
Cash From Financing Activities 481.2 -141 69.5 -35.9 788.7
Financing Cash Flow Items -0.9 0.9 -25 -57.8 -22.3
Issuance (Retirement) of Stock, Net -82.1 -106 31.6 8.2 15.8
Issuance (Retirement) of Debt, Net 564.2 -35.9 62.9 13.7 795.2
Foreign Exchange Effects 0.5 -0.3 -1 0.4 -0.2
Net Change in Cash 66.3 -45.2 453.5 55.6 -66.9
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -183 -223.8 -135.8 -60.1 -3.7
Cash From Operating Activities -186.6 -34.1 -126.9 -52.9 -37.3
Cash From Operating Activities 34.6 143.3 107.7 75.4 30.9
Deferred Taxes -8.4 -19 23 2.6 1.9
Non-Cash Items 9.6 64.9 51.9 28.2 12
Cash Taxes Paid 16.7 6.2 23.9 20 4.8
Cash Interest Paid 21.6 33 26.7 14.8 11.7
Changes in Working Capital -39.4 0.5 -173.7 -99 -78.4
Cash From Investing Activities -15.1 -381.3 -335.9 -64.3 -32.2
Capital Expenditures -15.1 -359.5 -335.9 -64.3 -32.2
Cash From Financing Activities -10.5 481.2 128.1 -101.2 -70.5
Financing Cash Flow Items -2.1 -0.9 -2.7 -2.4 -4.5
Issuance (Retirement) of Debt, Net -8.4 564.2 212.7 -16.9 -8.5
Foreign Exchange Effects -0.2 0.5 -0.6 0.4 -0.3
Net Change in Cash -212.4 66.3 -335.3 -218 -140.3
Issuance (Retirement) of Stock, Net 0 -82.1 -81.9 -81.9 -57.5
Other Investing Cash Flow Items, Total -21.8
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 15.2572 7904294 15972 2023-06-30 LOW
Millennium Management LLC Hedge Fund 5.2337 2711399 1429125 2023-08-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.1081 2646366 -1688003 2023-09-29 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.8753 1489585 -321344 2023-06-30 LOW
Two Sigma Investments, LP Hedge Fund 2.7387 1418825 463342 2023-06-30 HIGH
Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 2.5058 1298182 -9335 2023-06-30 MED
Hotchkis and Wiley Capital Management, LLC Investment Advisor 2.1897 1134420 190760 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.1849 1131955 -5662189 2023-09-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 2.0816 1078418 257198 2023-06-30 LOW
D. E. Shaw & Co., L.P. Hedge Fund 1.8876 977917 -385863 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7845 924484 28030 2023-06-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.6402 849734 -85692 2023-06-30 LOW
Bridgeway Capital Management, LLC Investment Advisor 1.6203 839433 34070 2023-06-30 MED
Invesco Capital Management LLC Investment Advisor 1.4291 740368 -72252 2023-06-30 LOW
Citadel Advisors LLC Hedge Fund 1.1995 621403 183944 2023-06-30 LOW
Rafferty Asset Management LLC Investment Advisor/Hedge Fund 1.1227 581625 198538 2023-06-30 MED
Palisade Capital Management, LLC Investment Advisor/Hedge Fund 1.0393 538418 24547 2023-06-30 LOW
Goldman Sachs & Company, Inc. Research Firm 0.9932 514552 -295380 2023-06-30 MED
Voloridge Investment Management, LLC Investment Advisor/Hedge Fund 0.9108 471872 -189900 2023-06-30 HIGH
Allspring Global Investments, LLC Investment Advisor/Hedge Fund 0.8755 453565 153850 2023-09-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Emergent BioSolutions Company profile

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, it offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, the company offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. Emergent BioSolutions Inc. has a development and manufacturing agreement with Novavax Inc. for coronavirus disease vaccine candidate. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Industry: Pharmaceuticals (NEC)

400 Professional Dr, Suite 400
GAITHERSBURG
MARYLAND 20879
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

US100

17,893.10 Price
-0.050% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 22:00 (UTC)
Spread 1.8

XRP/USD

0.56 Price
+0.780% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

77.62 Price
+0.140% 1D Chg, %
Long position overnight fee 0.0052%
Short position overnight fee -0.0272%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,033.77 Price
+0.130% 1D Chg, %
Long position overnight fee -0.0189%
Short position overnight fee 0.0106%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading